These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18781898)

  • 1. The heat shock protein 90 chaperone complex: an evolving therapeutic target.
    Barginear MF; Van Poznak C; Rosen N; Modi S; Hudis CA; Budman DR
    Curr Cancer Drug Targets; 2008 Sep; 8(6):522-32. PubMed ID: 18781898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
    Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
    Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
    McDowell CL; Bryan Sutton R; Obermann WM
    Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
    Prodromou C
    Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
    Zanphorlin LM; Alves FR; Ramos CH
    Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design.
    Verkhivker GM; Dixit A; Morra G; Colombo G
    Curr Top Med Chem; 2009; 9(15):1369-85. PubMed ID: 19860735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
    Koay YC; Wahyudi H; McAlpine SR
    Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
    Mak OW; Chand R; Reynisson J; Leung IKH
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Conformational Dynamics of Hsp90 and Its Interactors.
    Chavez JD; Schweppe DK; Eng JK; Bruce JE
    Cell Chem Biol; 2016 Jun; 23(6):716-26. PubMed ID: 27341434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
    Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
    Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90: Friends, clients and natural foes.
    Verma S; Goyal S; Jamal S; Singh A; Grover A
    Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function and regulation of the hsp90 machinery.
    Li J; Buchner J
    Biomed J; 2013; 36(3):106-17. PubMed ID: 23806880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
    Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
    Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.